PBA
ORKA

Paradigm Biocapital Advisors’s Oruka Therapeutics ORKA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204M Sell
2,144,526
-175,790
-8% -$11.7M 3.82% 7
2026
Q1 		$114M Buy
2,320,316
+610,000
+36% +$21.2M 2.33% 14
2025
Q4 		$51.8M Buy
+1,710,316
New +$47.7M 1.32% 19
2025
Q1 		– Sell
-819,660
Closed -$15.9M – 34
2024
Q4 		$15.9M Buy
819,660
+100,000
+14% +$2.44M 0.55% 27
2024
Q3 		$17.6M Buy
+719,660
New +$25M 0.6% 31

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Paradigm Biocapital Advisors's ORKA Position: Q2 2026 in Review

Paradigm Biocapital Advisors reduced its Oruka Therapeutics (ORKA) stake by 7.6% in Q2 2026, selling an estimated $11.7M and leaving 2,144,526 shares worth $204M. The position accounts for 3.82% of the portfolio, ranked #7.

Paradigm Biocapital Advisors first reported a position in ORKA in Q3 2024 and has held it in 5 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Paradigm Biocapital Advisors held 2,144,526 shares of Oruka Therapeutics worth $204M as of Q2 2026.
  • Paradigm Biocapital Advisors sold 175,790 Oruka Therapeutics shares in Q2 2026, an estimated $11.7M.
  • Oruka Therapeutics made up 3.82% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #7 holding.
  • Paradigm Biocapital Advisors first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.